Berenberg analyst Tom Jones lowered the firm’s price target on Grifols (GRFS) to EUR 15.25 from EUR 15.40 and keeps a Buy rating on the ...
In a report released yesterday, Tom Jones from Berenberg Bank maintained a Buy rating on Grifols (0RDU – Research Report), with a price target ...
Hosted on MSN4d
Spain: IBEX rises 0.80 % and now exceeds 12,870 points, driven by Grifols and the banking sectorThe selective Spanish stock market, the IBEX 35, continues to extend gains and is already up 0.80% at noon, standing above 12 ...
(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham City Research are counting on two different reports from a Spanish regulator to bolster their cases as they prepare to face off in ...
Morgan Stanley (NYSE:MS) resumed coverage on Grifols SA (NASDAQ:GRFS) (GRF:SM) (OTC: GIFOF) shares, issuing an Overweight rating and establishing a price target of €12.00. The firm's analysts ...
PR Newswire • 9 months ago Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C. The addition of the Clayton site in ...
Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which promises to provide a more reliable and easier treatment for patients.
The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results